[Table_StockNam基eRp础tTyp化e] 工 行业研究/行业周报 合成生物学周报：华熙生物在天津建成全球最大中试转化平台， 北京昌平合成生物企业数量激增近七成 执业证书号：S0010522110002 电话：13621792701 邮箱：wangqf@hazq.com 主要观点： [T行ab业le_周Su观m点mary] 公司价格与沪深 300 走势比较 华安证券化工团队发表的《合成生物学周报》是一份面向一级市 场、二级市场，汇总国内外合成生物学相关领域企业信息的行业周报。 目前生命科学基础前沿研究持续活跃，生物技术革命浪潮席卷全 球并加速融入经济社会发展，为人类应对生命健康、气候变化、资源 能源安全、粮食安全等重大挑战提供了崭新的解决方案。国家发改委 印发《"十四五"生物经济发展规划》,生物经济万亿赛道呼之欲出。 分析师：王强峰 合成生物学指数是华安证券研究所根据上市公司公告等汇总整 理由 60 家业务涉及合成生物学及其相关技术应用的上市公司构成并 以 2020 年 10 月 6 日为基准 1000 点，指数涵盖化工、医药、工业、 食品、生物医药等多领域公司。本周（2026/2/24-2026 ...

[Table_StockNam基eRp础tTyp化e] 工 行业研究/行业周报 合成生物学周报：华熙生物在天津建成全球最大中试转化平台， 北京昌平合成生物企业数量激增近七成 | 行业评级： | 增持 | | | --- | --- | --- | | 报告日期： | 2026-03-02 | [T行ab业le_周Su观m点mary] | 执业证书号：S0010522110002 电话：13621792701 邮箱：wangqf@hazq.com 主要观点： 1.【华安化工】基础化工：蓝星收购 混兑政策落地 2026-02-26 景气度有望迎来修复 2026-02-12 酮糖应用有望迎来爆发 2026-02-10 [T行ab业le_周Su观m点mary] 公司价格与沪深 300 走势比较 华安证券化工团队发表的《合成生物学周报》是一份面向一级市 场、二级市场，汇总国内外合成生物学相关领域企业信息的行业周报。 目前生命科学基础前沿研究持续活跃，生物技术革命浪潮席卷全 球并加速融入经济社会发展，为人类应对生命健康、气候变化、资源 能源安全、粮食安全等重大挑战提供了崭新的解决方案。国家发改委 印发《"十四五"生物经 ...

晨会纪要（R3） 晨会纪要 2026 年 03 月 02 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 4162.88 | 0.39 | | 深证成指 | 14495.09 | -0.06 | | 创业板指 | 3310.30 | -1.04 | | 科创 50 | 1488.02 | 0.15 | | 北证 50 | 1537.13 | -0.50 | | 沪深 300 | 4710.65 | -0.34 | 上证指数-沪深 300 走势图 -8% 2% 12% 22% 32% 2025-02 2025-05 2025-08 2025-11 上证指数 沪深300 | 何晨 | 分析师 | | --- | --- | | 执业证书编号:S0530513080001 | | | hechen@hnchasing.com | | | 周舒鹏 | 研究助理 | zhoushupeng@hnchasing.com 晨会聚焦 一、财信研究观点 【债券研究】债券市场综述 二、重要财经资讯 【宏观经济】中共中央政治局召开会议，讨论"十五五"规 ...

北交所策略专题报告 2026 年 03 月 01 日 2025 北交所业绩快报：五大行业均增收，化工新材利润修复领跑 ——北交所策略专题报告 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 2025 年北交所业绩快报出炉，化工新材实现营收+归母净利润同比增长 截至 2025 年 2 月 28 日北交所 2025 年业绩快报披露完毕，整体企业营收增速为 5.79%，归母净利润增速为-8.68%。从收入端来看，2025 年北交所企业营业收入 均值为 7.36 亿元，同比 2024 年均值增长 5.79%；中值为 4.19 亿元，同比 2024 年中值增长 0.05%。从利润端来看，2025 年北交所企业归母净利润均值为 4337 万元，同比 2024 年均值下滑 8.68%；中值为 2979 万元，同比 2024 年中值下滑 23.56%。从营收增速的分布维度来看，北交所 2025 年营收实现正增长的企业占 比 62.71%。2025 年北交所共有 185 家公司营收同比正增长，20 家公司增速超 40%。从归母净利润增速的分布维度来看，北交所 20 ...

（文章来源：证券日报） 证券日报网讯 2月27日，锦波生物发布2025年年度业绩快报公告称，公司2025年实现营业收入1，595， 372，919.28元，同比增长10.57%；归属于上市公司股东的净利润为651，175，616.96元，同比减少 11.08%。 ...

证券代码：920982 证券简称：锦波生物 公告编号：2026-009 山西锦波生物医药股份有限公司 一、2025 年年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 1,595,372,919.28 | 1,442,831,399.69 | 10.57% | | 利润总额 | 760,202,102.26 | 857,450,749.69 | -11.34% | | 归属于上市公司股 | 651,175,616.96 | 732,301,620.38 | -11.08% | | 东的净利润 | | | | | 归属于上市公司股 | 634,552,665.28 | 712,180,480.92 | -10.90% | | 东的扣除非经常性 | | | | | 损益的净利润 | | | | | 基本每股收益 | 5.66 | 6.36 | -11.01% | | 加权平均净资产收 | 37.35% | 58.41% | - | | 益率%（扣非前） | | | | | 加权平均净资产收 | 36.3 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流出5038.95万元，游资资金净流入1527.32万元，散 户资金净流入3511.63万元。医疗美容板块个股资金流向见下表： 证券之星消息，2月27日医疗美容板块较上一交易日下跌0.15%，锦波生物领跌。当日上证指数报收于 4162.88，上涨0.39%。深证成指报收于14495.09，下跌0.06%。医疗美容板块个股涨跌见下表： ...

Group 1 - The medical sector showed strong performance with the largest medical ETF (512170) initially rising over 1% and maintaining positive momentum, outperforming the broader market [1] - Over 1.15 billion CNY of net subscriptions were recorded for the medical ETF, indicating strong investor interest [1] - The ETF has a total scale of 27.7 billion CNY, making it the largest in the medical and healthcare category [3] Group 2 - Huatai Medical reported an expected revenue of 2.584 billion CNY for 2025, representing a year-on-year increase of 25%, with net profit projected at 821 million CNY, up 22% [3] - Other companies within the medical ETF, such as United Imaging and Yirui Technology, are also expected to see net profit growth exceeding 40% [3] - The medical ETF consists of over 50% medical device weight and more than 25% CXO content, covering 12 AI medical and brain-machine interface concept stocks [3] Group 3 - The performance of constituent stocks within the ETF varied, with Huatai Medical leading the gains, rising nearly 7%, while major stocks like Mindray and United Imaging saw declines of nearly 1% [2][3]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of over 1.15 billion yuan in recent trading sessions [1][5]. Group 1: ETF Performance - The healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1]. - As of February 24, 2026, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year growth of 25%, with a net profit of 821 million yuan, up 22% [3][4]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3]. Group 3: Market Trends - The healthcare sector is characterized by a mix of rising and falling stocks, with Huatai Medical leading gains by rising nearly 7% after a strong earnings report, while major stocks like Mindray and United Imaging saw declines of nearly 1% [1][3].

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].